Código QR

A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review

Selective rearranged during transfection (RET) tyrosine kinase inhibitor, pralsetinib, demonstrated clinical efficacy and was well tolerated in lung and thyroid cancers with RET gene mutations or fusions in clinical trials. While the latter focused on the risk of pneumonitis, there is a lack of data...

Descrición completa

Gardado en:
Principais autores: François Poumeaud, Marion Jaffrelot, Carlos Gomez-Roca, Iphigénie Korakis, Giulia Leonardi, Marine Joly, Julien Mazières, Rosine Guimbaud, Nadim Fares, Emily Alouani
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2024-07-01
Series:Frontiers in Medicine
Assuntos:
pralsetinib
RET inhibitor
infection
JAK/STAT
case report
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fmed.2024.1402902/full
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares